On November 21, Pfizer and zai lab announced a global strategy for the new antibacterial drug Dingo Lida (sulbactam sodium-dalbavancin sodium) in mainland china, with a subsidiary of Pfizer being exclusively responsible for the commercialization operation of the product in mainland china. The new antibacterial drug Dingo Lida is currently the only antibacterial drug specifically developed for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). The product was approved in 2023 and 2024 in the usa and mainland china, respectively.
辉瑞与再鼎医药就新型抗菌药物鼎优乐达成在中国内地的合作
Pfizer and zai lab have reached a cooperation agreement for the new antibacterial drug Dingo Lida in mainland china.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated